Source-grounded facts extracted from ProPhase Labs, Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
ProPhase Labs, Inc. issued up to 240,369 shares of common stock of warrant to Generating Alpha Ltd..
“In connection with entering into the Agreement, the Company issued 549,105 shares of common stock and a prefunded common stock purchase warrant to acquire up to 240,369 shares of common stock as a commitment fee.”
ProPhase Labs, Inc. issued 549,105 shares of common stock to Generating Alpha Ltd..
“In connection with entering into the Agreement, the Company issued 549,105 shares of common stock and a prefunded common stock purchase warrant to acquire up to 240,369 shares of common stock as a commitment fee.”
ProPhase Labs, Inc. entered into Stock Purchase Agreement with Generating Alpha Ltd. valued at ten million dollars ($10,000,000) (effective 2026-01-16).
“On January 16, 2026, ProPhase Labs, Inc. (“the Company”) entered into a Stock Purchase Agreement (“the Agreement”) with Generating Alpha Ltd. (“the Investor”), pursuant to which the Investor committed to provide the Company with up to ten million dollars ($10,000,000) of equity capital over time, at the Company’s election and subject to the terms and conditions set forth in the Agreement.”
ProPhase Labs, Inc. received a nasdaq delisting notice notice regarding minimum bid price (rules 5550(a)(2)).
“December 29, 2025, ProPhase Labs, Inc. (the “Company”) received a letter from the staff of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Company did not regain compliance with Nasdaq Listing Rule 5550(a)(2), which requires a minimum bid price of $1.00 per share. As previously disclosed, the Company was provided an initial 180-day compliance period, followed by an additional 180-day compliance period, to regain compliance with the minimum bid price requirement, which expired on December 22, 2025. Nasdaq indicated that trading of the Company’s common stock will be suspended at the o”
ProPhase Labs, Inc.: Amended Certificate of Incorporation to effect a 1-for-10 reverse stock split (effective 2025-12-02).
“On December 2, 2025, ProPhase Labs, Inc., a Delaware corporation (the “Company”), filed a Certificate of Amendment (the “Certificate of Amendment”) to its Certificate of Incorporation with the Secretary of State of the State of Delaware to effect a 1-for-10 reverse stock split of the Company’s issued and outstanding shares of common stock, par value $0.0005 per share (the “Common Stock”) (the “Reverse Stock Split”).”
ProPhase Labs, Inc.: Amended Certificate of Incorporation to effect a 1-for-10 reverse stock split of common stock (effective 2025-12-02).
“On December 2, 2025, ProPhase Labs, Inc., a Delaware corporation (the “Company”), filed a Certificate of Amendment (the “Certificate of Amendment”) to its Certificate of Incorporation with the Secretary of State of the State of Delaware to effect a 1-for-10 reverse stock split of the Company’s issued and outstanding shares of common stock, par value $0.0005 per share (the “Common Stock”) (the “Reverse Stock Split”). The Certificate of Amendment became effective on December 2, 2025.”
ProPhase Labs, Inc.: Amended Certificate of Incorporation to effect a 1-for-10 reverse stock split (effective 2025-12-02).
“On November 30, 2025, the Company’s stockholders approved an amendment to the Company’s Certificate of Incorporation to effect a reverse stock split of the Company’s common stock at a ratio of one (1) shares for every ten (10) shares of common stock outstanding. The amendment became effective on December 2, 2025.”
ProPhase Labs, Inc.: Updated principal office address to RXR Plaza, Uniondale, New York (effective 2025-09-09).
“stockholders approved an amendment to the Company’s Amended and Restated Bylaws to update the Company’s principal office address to RXR Plaza, Uniondale, New York (Proposal 6).”
ProPhase Labs, Inc.: Increased number of authorized shares of common stock from 50,000,000 to 1,000,000,000 (effective 2025-09-09).
“stockholders also approved Certificate of Amendment to its Amended and Restated Certificate of Incorporation to increase the number of authorized shares of common stock from 50,000,000 to 1,000,000,000.”
ProPhase Labs, Inc. received a nasdaq deficiency notice notice regarding other (rules 5605(c)(2)(A), 5605(c)(4), 5605(c)(2), 5605).
“mittee effective July 19, 2025, the day following the Company’s 2025 Annual Meeting. In response to the Company’s notification of Ms. Abenante’s appointment to the Board, on June 25, 2025, the Company received a letter from Nasdaq informing the Company that it was now in compliance with Nasdaq Rule 5605(c)(2) and that the matter is now closed. Forward-Looking Statements This Current Report on Form 8-K contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements”
ProPhase Labs, Inc. incurred loan of $500,000 with Ted Karkus and an unaffiliated investor at 10% maturing twelve (12) months from the execution date.
“the Loan Agreement constitutes a related party transaction under Item 404(a) of Regulation S-K. The material terms of the loan are a non-convertible loan in the amount of $500,000, with a 20% original issue discount. The loan bears interest at an annual rate of 10% and matures twelve (12) months from the execution date. The Company will pay Mr. Karkus a”
ProPhase Labs, Inc. incurred loan of $500,000 with Ted Karkus at 10% maturing twelve (12) months from the execution date.
“the Loan Agreement constitutes a related party transaction under Item 404(a) of Regulation S-K. The material terms of the loan are a non-convertible loan in the amount of $500,000, with a 20% original issue discount. The loan bears interest at an annual rate of 10% and matures twelve (12) months from the execution date. The Company will pay Mr. Karkus a”
ProPhase Labs, Inc. received a nasdaq extension granted notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A), 5810(c)(3)(A)(ii)).
“June 25, 2025, the Company received a letter from the Nasdaq staff advising that the Company had been granted a 180-day extension to December 22, 2025 to regain compliance with the Minimum Bid Price Requirement, in accordance with Nasdaq Listing Rule 5810(c)(3)(A). The Company intends to continue actively monitoring the closing bid price for the Company’s common stock between now and December 22, 2025, and will consider available options to resolve the deficiency to regain compliance with the Minimum Bid Price Requirement. To regain compliance, the Company’s Class A ordinary shares must have a”
Carolina Abenante was appointed as independent director at ProPhase Labs, Inc..
“On June 20, 2025, the Board of Directors (the “Board”) of ProPhase Labs, Inc. (the “Company”) appointed Carolina Abenante, Esq. to serve as an independent director to fill the existing vacancy on the Board.”
Stuart Hollenshead was appointed as Chief Operating Officer at ProPhase Labs, Inc..
“On February 18, 2025, ProPhase Labs, Inc. (the “Company”) announced that Stuart Hollenshead has been appointed to serve as Chief Operating Officer of the Company, effective on February 17, 2025, to replace Jed Latkin, who as previously reported, stepped down as Chief Operating Officer effective February 14, 2025 to pursue other business opportunities.”
Jed Latkin departed as Chief Operating Officer at ProPhase Labs, Inc..
“On February 18, 2025, ProPhase Labs, Inc. (the “Company”) announced that Stuart Hollenshead has been appointed to serve as Chief Operating Officer of the Company, effective on February 17, 2025, to replace Jed Latkin, who as previously reported, stepped down as Chief Operating Officer effective February 14, 2025 to pursue other business opportunities.”
Stuart Hollenshead was appointed as Chief Operating Officer at ProPhase Labs, Inc..
“ProPhase Labs, Inc. (the “Company”) is in final stages of negotiation with Stuart Hollenshead to be the new Chief Operating Officer of the Company.”
Jed Latkin resigned as Chief Operating Officer at ProPhase Labs, Inc..
“Jed Latkin, Chief Operating Officer of the Company, provided notice to the Company on February 7, 2025, that he would be leaving the Company effective February 14, 2025 to pursue other business opportunities.”
ProPhase Labs, Inc. completed a disposition involving JL Projects, Inc. (closed 2025-01-16).
“The transaction closed concurrently with the execution of the Agreement on January 16, 2025.”
ProPhase Labs, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).
“December 26, 2024, ProPhase Labs, Inc. (the “Company”) received a letter from the Listing Qualifications Staff (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that the bid price for the Company’s common stock for the last 30 consecutive business days had closed below the minimum $1.00 per share required for continued listing under Nasdaq Listing Rule 5550(a)(2). Under Nasdaq Listing Rule 5810(c)(3)(A), the Company has been granted a 180 calendar day grace period, or until June 24, 2025, to regain compliance with the minimum bid price requirement. The continued listing standa”
ProPhase Labs, Inc. engaged Fruci & Associates II, PLLC as its auditor.
“ctober 18, 2024, the Company engaged Fruci & Associates II, PLLC (the “ New Accountant ”) as its new independent registered public accounting firm for the fiscal year ending December 31, 2024. The engagement of the New Accountant was approved by the Company’s board of directors. During the two most recent fiscal years ended December 31, 2023 and 2022 and through the date the Company selected the New Accountant as its independent registered public accounting firm, neither the Company nor anyone on behalf of the Company consulted the New Accountant regarding”
Morison Cogen LLP resigned as auditor of ProPhase Labs, Inc..
“Morison Cogen LLP resigned as the independent registered public accounting firm of the Company, effective as of September 30, 2024.”
Eleanor McBrier resigned as director at ProPhase Labs, Inc..
“On September 20, 2024, Eleanor McBrier notified the Board of her intention to resign as director of the Company, effective immediately.”
ProPhase Labs, Inc. reported financial results for the three months ended March 31, 2024.
“ProPhase Labs, Inc. (the “Company”) issued a press release announcing its financial results for the first quarter ended March 31, 2024.”
ProPhase Labs, Inc. reported financial results for first quarter ended March 31, 2024.
“On May 9, 2024, ProPhase Labs, Inc. (the “Company”) issued a press release announcing its financial results for the first quarter ended March 31, 2024.”
Jed Latkin was appointed as Chief Operating Officer at ProPhase Labs, Inc..
“Mr. Latkin was appointed to serve as Chief Operating Officer of the Company, effective on January 1, 2024.”
ProPhase Labs, Inc. entered into Standstill Agreement with ThinkEquity LLC (effective 2024-04-18).
“On April 18, 2024, ProPhase Labs, Inc. (the “Company”) entered into a standstill agreement with ThinkEquity LLC (the “Sales Agent”) (such agreement, the “Standstill Agreement”).”
ProPhase Labs, Inc. reported financial results for the full-year ended December 31, 2023.
“On March 15, 2024, ProPhase Labs, Inc. (the “Company”) issued a press release announcing its financial results for the year ended December 31, 2023.”
Robert A. Morse changed role as Controller at ProPhase Labs, Inc..
“Robert A. Morse mutually agreed that Mr. Morse would cease to be Chief Financial Officer of the Company and resume his role as Controller of the Company, effective January 1, 2024,”
Jed A. Latkin was appointed as Chief Operating Officer at ProPhase Labs, Inc..
“Jed A. Latkin has been appointed to serve as Chief Operating Officer of the Company, effective on January 1, 2024.”
ProPhase Labs, Inc. reported financial results for the three and nine months ended September 30, 2023.
“ProPhase Labs, Inc. (the “Company”) issued a press release announcing its financial results for the third quarter ended September 30, 2023.”
ProPhase Labs, Inc. reported the three months ended June 30, 2023 results: net income adjusted EBITDA loss for the quarter ended June 30,2023 was $2.2 million.
“On August 10, 2023, ProPhase Labs, Inc. (the “Company”) issued a press release announcing its financial results for the second quarter ended June 30, 2023.”
ProPhase Labs, Inc. shareholders approved Approval of the Amended and Restated 2022 Directors’ Equity Compensation Plan.
“The Amended 2022 Directors’ Plan was approved by the following vote: For Against Abstain Broker Non- Votes 11,040,479 991,383 21,573 3,035,580”
ProPhase Labs, Inc. shareholders approved Approval of the Amended and Restated 2022 Equity Compensation Plan.
“The Amended 2022 Plan was approved by the following vote: For Against Abstain Broker Non- Votes 11,415,903 619,094 14,438 3,035,580”
ProPhase Labs, Inc. shareholders approved Ratification of the Appointment of Independent Auditors at the 2023-12-31 meeting.
“The ratification of the appointment by the Audit Committee of the board of directors of Morison Cogen LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023 was approved by the following vote: For Against Abstain Broker Non- Votes 15,066,019 15,111 7,885 3,035,580”
ProPhase Labs, Inc. shareholders approved Election of Directors.
“Each of the nominees for election to the board of directors was elected to hold office for a one-year term and until their respective successors are elected and qualified by the following votes: Name For Withheld Broker Non- Votes Ted Karkus 12,023,672 29,763 3,035,580 Jason Barr 10,721,866 1,331,569 3,035,580 Louis Gleckel, MD 10,602,209 1,451,226 3,035,580 Warren Hirsch 11,152,966 900,469 3,035,580”
ProPhase Labs, Inc.: Amended and restated bylaws to address universal proxy rules and make procedural changes consistent with recent DGCL amendments (effective 2023-06-16).
“On June 16, 2023, the board of directors (the “Board”) of ProPhase Labs, Inc. (the “Company”) amended and restated the Company’s bylaws in order to (i) address the universal proxy rules recently adopted by the U.S. Securities and Exchange Commission, by clarifying that no person may solicit proxies in support of a director nominee other than the Board’s nominees unless such person has complied with Rule 14a-19 under the Securities Exchange Act of 1934, as amended, including applicable notice and solicitation requirements and (ii) to make certain other procedural changes consistent with recent changes to the Delaware General Corporation Law.”
ProPhase Labs, Inc. reported the three months ended March 31, 2023 results: revenue $19.3 million, net income $0.6 million, or $0.03 per diluted share.
“growth. ● Implemented new $6 million stock repurchase program. Financial highlights for the three months ended March 31, 2023, include the following: ● Net revenue of $19.3 million for the three months ended March 31, 2023, as compared to $47.5 million for the three months ended March 31, 2022. ● Net Income of $0.6 million, or $0.03 per diluted share, for”
Robert A. Morse, Jr. changed role as Chief Financial Officer at ProPhase Labs, Inc..
“On April 4, 2023, Robert A. Morse, Jr. was promoted to the position of Chief Financial Officer of ProPhase Labs, Inc. (the “Company”).”
ProPhase Labs, Inc. reported the year ended December 31, 2022 results: revenue $122.6 million, net income $18.5 million, EPS $1.17 per diluted share.
“Financial highlights for the full year ended December 31, 2022, include the following: ● Net revenue of $122.6 million for the year ended December 31, 2022, as compared to $79.0 million for the year ended December 31, 2021, an increase of approximately 55%. ● Net Income of $18.5 million, or $1.17 per diluted share, for the year ended December 31, 2022, as compared to net income of $6.3 million, or $0.41 per share, for the year ended December 31, 2021.”
ProPhase Labs, Inc. incurred guarantee of $7.6 million with JXVII Trust at 10% per year maturing January 27, 2026.
“On January 26, 2023, ProPhase Labs, Inc. (the “Company”) issued an unsecured promissory note and guaranty for an aggregate principal amount of $7.6 million (the “Note”) to JXVII Trust (“JXVII”).”
Robert A. Morse, Jr. was appointed as principal financial officer and principal accounting officer at ProPhase Labs, Inc..
“Robert A. Morse, Jr., Controller of the Company, will assume the role of principal financial officer and principal accounting officer of the Company as of the Effective Date.”
Monica Brady resigned as Chief Accounting Officer at ProPhase Labs, Inc..
“On December 23, 2022, Monica Brady, Chief Accounting Officer of ProPhase Labs, Inc. (the “Company”), provided notice to the Company that she would be leaving the Company effective January 13, 2023 (the “Effective Date”) to pursue other business opportunities.”
ProPhase Labs, Inc. entered into Asset Purchase Agreement with Stella Diagnostics Inc. and Stella DX, LLC valued at $3,486,000 in cash (effective 2022-12-15).
“On December 15, 2022, ProPhase Labs, Inc. (the “Company”) entered into an Asset Purchase Agreement (the “Purchase Agreement”), by and among the Company and Stella Diagnostics Inc. (“Stella”) and Stella DX, LLC (“Stella DX” and, together with Stella, the “Sellers”), pursuant to which the Company will purchase all of the assets, rights and interests of the Sellers and their affiliates pertaining to the Sellers’ BE-Smart Esophageal Pre-Cancer diagnostic screening test and certain clinical assets, including all intellectual property rights (the “Purchased Assets”).”
ProPhase Labs, Inc. reported the third quarter ended September 30, 2022 results: revenue $24.2 million, net income $1.0 million, or $0.06 per share, EPS $0.06 per share.
“Current Report on Form 8-K. --- EX-99.1 () --- EX-99.1 2 ex99-1.htm Exhibit 99.1 ProPhase Labs Announces Record Third Quarter 2022 Financial Results Q3 2022 Net Revenues of $24.2 Million (a Q3 record); Up 155% Year-over-Year Q3 2022 Net Income of $1.0 Million versus a loss in Q3 2021 Q3 2022 adjusted EBITDA of $6.3 million (a Q3 record) versus a loss in Q3 2021”
Bill White departed as Chief Financial Officer at ProPhase Labs, Inc..
“On October 4, 2022 (the “Effective Date”), ProPhase Labs, Inc. (the “Company”) and Bill White, the Company’s Chief Financial Officer, agreed to Mr. White’s voluntary separation of employment from the Company, effective as of the Effective Date.”
Monica Brady changed role as Chief Accounting Officer and Chief Financial Officer of subsidiary at ProPhase Labs, Inc..
“Ms. Brady will remain with the Company and continue to serve as the Company’s Chief Accounting Officer, and Chief Financial Officer of the Company’s wholly-owned subsidiary, ProPhase Diagnostics, Inc., as of the Effective Date.”
Bill White was appointed as Chief Financial Officer at ProPhase Labs, Inc..
“On May 9, 2022, ProPhase Labs, Inc. (the “Company”) announced that it will appoint Bill White, age 61, as Chief Financial Officer of the Company, effective May 23, 2022”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.